28 March 2022 - Deborah Wilkes
- Norgine hires Lupin’s Alan Butcher
- Neuraxpharm appoints first country manager for Portugal
Norgine hires Lupin’s Alan Butcher
Norgine has hired Alan Butcher as chief corporate development officer and a member of its Executive Committee.
Butcher joins the Netherlands-based specialty pharmaceutical company from Lupin where he was chief corporate development officer. He has also worked for AMAG Pharmaceuticals, Endo, GlaxoSmithKline, Purdue Pharma and Shire Pharmaceuticals.
At Norgine, he will be responsible for all corporate development, with a focus on in-licensing rights to innovative pipeline products in Europe and Australia/New Zealand, as well as mergers and acquisitions.
Butcher will be based in the US.
Neuraxpharm appoints first country manager for Portugal
Neuraxpharm has promoted Monica Torrecilla to its first country manager for Portugal.
The company established its operations in Portugal in November 2019. Torrecilla, who is marketing manager for Neuraxpharm Spain, played a key role in defining the strategy and product selection for the “greenfield” launch of Neuraxpharm Portugal.
Torrecilla has been with Neuraxpharm Spain for almost five years. Prior to joining Neuraxpharm, she led the Consumer Health Care business unit for Bausch & Lomb.
Neuraxpharm, which was known as NuPharm Group until October 2018, has been owned by private-equity firm Permira since 2020.
The German company’s goal is to be the “European leader in pharmaceutical products for treatment of the central nervous system (CNS)”.
Neuraxpharm has a direct presence in key European countries including Austria, the Czech Republic, France, Germany, Greece, Hungary, Ireland, Italy, Poland, Portugal, Slovakia, Spain and the UK.